It was a busy December for the FDA as it gave the green light to five more new molecular entities (NMEs), boosting the number of NME and new therapeutic biological products approved by the agency in 2015 to 45, an almost 10 percent increase over the 41 NMEs that were approved last year. Read More
The biotech sector managed to eke out a small gain in 2015 despite the turbulent capital markets for most of the second half of the year. Helping keep the industry above water was the stellar performance of 13 companies that saw their share prices double in 2015*. Read More
